Juno Therapeutics, Kite Pharma, Eleven Bio Lead Monday's After-Hours Movers
Juno Therapeutics Inc (NASDAQ: JUNO) gained nearly 50 percent to $69.16 after the bell before falling off slightly. The company obtained regulatory approval for an investigational new drug application concerning its B cell non-Hodgkin lymphoma treatment.
Kite Pharma Inc (NASDAQ: KITE) rose 11 percent to $65.50. The company didn't issue news but is developing a gene therapy platform that has been compared with Juno's technology.
Eleven Biotherapeutics Inc (NASDAQ: EBIO) picked up 4.6 percent, trading at $2.95 after hours. The company didn't issue news.
Assured Guaranty Ltd. (NYSE: AGO) bounced up nearly 3 percent in late trading to $24.44. The company, which provides credit protection products to U.S. and international public finance, was off more than 13 percent before the bell Monday.
Intrexon Corp (NYSE: XON) rose 2.7 percent to $48.50. The company closed down earlier by 2.2 percent and didn't issue news.
Apollo Education Group Inc (NASDAQ: APOL) dropped 5 percent to $14.75 in late trading. The education services provider posted third quarter results after the bell Monday.
500.com Ltd (NYSE: WBAI) fell nearly 2.8 percent to $24.75 in the extended session. Earlier Monday, the online sports lottery service provider in China completed a private placement of 63.5 million shares at the equivalent of $19.50 per American depositary receipt.
Xunlei Ltd (NASDAQ: XNET) declined 2 percent to $11.25. The shares closed down more than 5 percent earlier. Xunlei, which provides an Internet platform in China, didn't issue news.
Hewlett-Packard Company (NYSE: HPQ) was off by 1.8 percent to $29.44 after the bell. The shares closed down by 1.9 percent and reportedly had its target price cut by Jefferies.
Aratana Therapeutics Inc (NASDAQ: PETX) dipped 1 percent to $14.70. The veterinary medicine company closed up earlier by more than 10 percent after it announced positive results from a study of its drug for appetite stimulation for dogs.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.